Adaptimmune Therapeutics plc

ADAP · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$71-$114-$165-$158
Dep. & Amort.$11$9$6$7
Deferred Tax$0$0$0$6
Stock-Based Comp.$12$12$18$21
Change in WC-$37-$25-$2$135
Other Non-Cash$11-$24$1$7
Operating Cash Flow-$73-$141-$142$11
Investing Activities
PP&E Inv.-$3-$5-$30-$9
Net Acquisitions$0$45$78$0
Inv. Purchases-$100-$76-$48-$140
Inv. Sales/Matur.$44$211$167$224
Other Inv. Act.$0$1-$78-$0
Investing Cash Flow-$59$177$89$76
Financing Activities
Debt Repay.$50$0$0$0
Stock Issued$29$1$13$3
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$1
Financing Cash Flow$79$1$13$3
Forex Effect-$0$1-$2$0
Net Chg. in Cash-$54$37-$42$90
Supplemental Information
Beg. Cash$147$110$152$61
End Cash$93$147$110$152
Free Cash Flow-$76-$146-$172$2